AngioDynamics Inc. (NASDAQ:ANGO) was up 4.7% during mid-day trading on Wednesday . The stock traded as high as $14.73 and last traded at $14.49, with a volume of 149,799 shares traded. The stock had previously closed at $13.84.

Several equities research analysts recently issued reports on ANGO shares. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a report on Wednesday, June 8th. Canaccord Genuity downgraded AngioDynamics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $14.50 to $13.00 in a report on Tuesday, April 5th. Piper Jaffray Cos. started coverage on AngioDynamics in a report on Friday, April 8th. They set a “neutral” rating and a $12.00 price target for the company. Finally, KeyCorp decreased their price target on AngioDynamics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, April 8th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $14.10.

The firm has a 50-day moving average of $13.13 and a 200-day moving average of $11.90. The firm’s market cap is $525.61 million.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, April 7th. The company reported $0.15 EPS for the quarter, beating the Zacks’ consensus estimate of $0.14 by $0.01. The firm earned $87.40 million during the quarter. During the same period in the previous year, the firm posted $0.12 EPS. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. Equities analysts expect that AngioDynamics Inc. will post $0.56 EPS for the current year.

In related news, VP Charles R. Greiner sold 3,508 shares of the firm’s stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $12.31, for a total transaction of $43,183.48. Following the completion of the transaction, the vice president now owns 20,910 shares of the company’s stock, valued at approximately $257,402.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Stephen A. Trowbridge sold 12,940 shares of the firm’s stock in a transaction that occurred on Monday, April 25th. The shares were sold at an average price of $12.30, for a total value of $159,162.00. Following the transaction, the senior vice president now directly owns 32,469 shares of the company’s stock, valued at approximately $399,368.70. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors recently bought and sold shares of the stock. Nationwide Fund Advisors raised its position in AngioDynamics by 252.9% in the fourth quarter. Nationwide Fund Advisors now owns 88,374 shares of the company’s stock worth $1,073,000 after buying an additional 63,332 shares during the period. Morgan Stanley raised its position in AngioDynamics by 6.2% in the fourth quarter. Morgan Stanley now owns 98,634 shares of the company’s stock worth $1,198,000 after buying an additional 5,728 shares during the period. Principal Financial Group Inc. raised its position in AngioDynamics by 5.2% in the fourth quarter. Principal Financial Group Inc. now owns 174,319 shares of the company’s stock worth $2,116,000 after buying an additional 8,640 shares during the period. Royce & Associates LLC raised its position in AngioDynamics by 19.0% in the fourth quarter. Royce & Associates LLC now owns 640,801 shares of the company’s stock worth $7,779,000 after buying an additional 102,098 shares during the period. Finally, Whitebox Advisors LLC bought a new position in AngioDynamics during the fourth quarter worth $1,384,000.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.